drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate consisting of a humanized anti–Trop‑2 IgG1 linked via a cleavable linker to SN‑38 (the active metabolite of irinotecan, a topoisomerase I inhibitor). It binds Trop‑2 on tumor cells, is internalized, and releases SN‑38 to inhibit topoisomerase I, causing DNA damage and cell death, with potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Sacituzumab Govitecan-hziy
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti–Trop-2 IgG1 antibody linked via a cleavable linker to SN-38 (topoisomerase I inhibitor). After binding Trop-2 on tumor cells and internalization, SN-38 is released intracellularly to inhibit topoisomerase I, inducing DNA damage, cell-cycle arrest, and apoptosis; the cleavable linker can enable a bystander effect.
drug_name
Sacituzumab govitecan (Trodelvy)
nct_id_drug_ref
NCT06240195